Bright Minds Biosciences Inc. (DRUG)
NASDAQ: DRUG · Real-Time Price · USD
71.46
-0.26 (-0.36%)
At close: Apr 2, 2026, 4:00 PM EDT
72.88
+1.42 (1.99%)
After-hours: Apr 2, 2026, 7:48 PM EDT

Bright Minds Biosciences Stock Forecast

Stock Price Forecast

The 3 analysts that cover Bright Minds Biosciences stock have a consensus rating of "Strong Buy" and an average price target of $124, which forecasts a 73.52% increase in the stock price over the next year. The lowest target is $80 and the highest is $147.

Price Target: $124 (+73.52%)
Analyst Consensus: Strong Buy
TargetLowAverageMedianHigh
Price$80$124$145$147
Change+11.95%+73.52%+102.91%+105.71%

Analyst Ratings

The average analyst rating for Bright Minds Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

RatingNov '25Dec '25Jan '26Feb '26Mar '26Mar '26
Strong Buy555544
Buy433111
Hold000000
Sell000000
Strong Sell000000
Total988655

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
BTIG
BTIG
Strong Buy
Reiterates
$147
Strong BuyReiterates$147+105.71%Mar 30, 2026
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Maintains
$115$145
Strong BuyMaintains$115$145+102.91%Mar 4, 2026
BTIG
BTIG
Strong Buy
Maintains
$147
Strong BuyMaintains$147+105.71%Feb 17, 2026
BTIG
BTIG
Strong Buy
Maintains
$72$147
Strong BuyMaintains$72$147+105.71%Jan 7, 2026
BTIG
BTIG
Strong Buy
Maintains
$72$147
Strong BuyMaintains$72$147+105.71%Jan 6, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
n/a
EPS Next Year
n/a
No financial forecasts available for this stock

Revenue Forecast

No data available

Revenue Growth

No data available

EPS Forecast

No data available

EPS Growth

No data available
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.